- Home
- RNTX vs AEON Comparison
RNTX vs AEON Comparison
Compare RNTX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNTX | AEON |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | 11 | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 26.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RNTX | AEON |
|---|---|---|
| Price | $1.33 | $1.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $7.20 |
| AVG Volume (30 Days) | ★ 87.1K | 71.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.38 |
| 52 Week High | $2.22 | $1.45 |
Technical Indicators
Market Signals| Indicator | RNTX | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 51.94 |
| Support Level | $1.34 | $0.69 |
| Resistance Level | $1.57 | $1.42 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 68.42 | 58.88 |
Price Performance
Historical ComparisonAbout RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.